XML 61 R50.htm IDEA: XBRL DOCUMENT v3.24.3
RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)
 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Dec. 29, 2023
Jun. 28, 2023
Feb. 28, 2023
May 17, 2022
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2023
Interest income         $ 101,236 $ 110,596 $ 309,031 $ 555,281  
Principal repayments             $ 26,408 118,847  
Common stock share issued         23,346,023   23,346,023   15,982,472
Accounts receivable balance         $ 17,484,240   $ 17,484,240   $ 19,759,254
Prepaid expenses and other current assets - related party         1,914,881   1,914,881   1,811,911
Revenue         $ 12,411,048 12,823,797 40,202,238 37,537,003  
Basotho Investment Limited [Member]                  
General and administrative expenses             $ 92,700   $ 10,300
Common stock share issued         92,700   92,700   120,000
Grigorios Siokas [Member]                  
Outstanding principal balance         $ 21,158   $ 21,158   $ 13,257
Foreign curreny translation             1,525    
Cana Holdings Laboratories Holding Limited [Member]                  
Secured promissory note     $ 4,457,520            
Description related to interest on principal     Interest on the Principal Amount under this Note shall accrue at a rate equal to Five Percent (5%) plus 1 month LIBOR per annum (5.47% as of December 31, 2023)            
DOC Pharma S.A. [Member]                  
Interest income             143,000    
Principal repayments             334,350 135,467  
Interest repayments             $ 155,440    
Interest rate             5.50%    
Loan term             10 years    
Maturity date             Dec. 31, 2032    
Accounts payable and accrued expenses - related party         72,968   $ 72,968   34,217
Prepaid balance                 4,279,200
Accounts receivable - related party         2,448,517   2,448,517   2,386,721
Prepaid expenses and other current assets - related party         6,393,642   $ 6,393,642   4,347,184
Agreement terminate             Dec. 31, 2025    
Pieces per product             1,000 pieces    
Purchased of additional licenses             $ 525,461    
Loan current portion         445,800   445,800   442,480
Loan non-current portion         3,232,050   3,232,050   3,539,840
Revenue         40,370 61,163 581,862 43,107  
Inventroy purchase         85,073 456,257 510,711 1,057,621  
Purchase of branded pharmaceuticals $ 3,539,840 $ 1,965,600              
Description of research and development       The total cost of this project will be €1,425,000 plus VAT and will be done over three phases as follows: Design & Development (€725,000); Control and Product Manufacturing (€250,000) and Clinical Study and Research (€450,000). SkyPharm has bought a total of as of 81 licenses at value of €554,500 ($593,204) which is 38.91% of the total cost, as of December 31, 2022. During the year ended December 31, 2023, 24 additional licenses were purchased at value of €475,014 ($525,461)          
Monthly basis instalments         37,150   37,150    
DOC Pharma S.A. [Member] | Inventories Related Agreement [Member]                  
Inventroy purchase         38,096 455,586 175,123 1,048,557  
Dimitrios Goulielmos [Member]                  
Outstanding principal balance         11,368   11,368   11,283
Foreign curreny translation             85    
Panagiotis Kozaris [Member]                  
Shares owned         0 51,159      
Prepaid expenses         194,215   194,215   194,215
Maria Kozari [Member]                  
Accounts receivable balance         1,123,835   1,123,835   1,142,402
Net sales         113,161 $ 310,126 122,969 $ 359,760  
George Terzis [Member]                  
Unpaid salaries and bonuses         731,000   731,000   98,000
Unpaid salaries and bonuses dues         188,000   188,000    
Kanarogloy & Sia Epe [Member]                  
Accounts payable and accrued expenses - related party         $ 29,832   $ 29,832   $ 85,332